HENAN TALOPH PHARMACEUTICAL STOCK CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.22 CNY | -0.38% |
|
+2.55% | -14.85% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 1,951 | 2,505 | 2,735 | 5,056 | 3,544 | 3,429 |
| Enterprise Value (EV) 1 | 2,359 | 3,066 | 3,365 | 5,615 | 3,824 | 3,859 |
| P/E ratio | -16.9 x | 55.6 x | 93.6 x | 839 x | -49.6 x | 79.2 x |
| Yield | - | - | 0.32% | 0.11% | - | - |
| Capitalization / Revenue | 1.63 x | 1.91 x | 1.93 x | 3.15 x | 1.81 x | 1.66 x |
| EV / Revenue | 1.97 x | 2.34 x | 2.37 x | 3.5 x | 1.95 x | 1.86 x |
| EV / EBITDA | 20.7 x | 21 x | 28.7 x | 34.2 x | 97.1 x | 30.4 x |
| EV / FCF | -169 x | -31.2 x | -95.2 x | 45.2 x | 10.6 x | -39 x |
| FCF Yield | -0.59% | -3.21% | -1.05% | 2.21% | 9.45% | -2.57% |
| Price to Book | 1.41 x | 1.91 x | 1.88 x | 3.04 x | 2.3 x | 2.17 x |
| Nbr of stocks (in thousands) | 573,886 | 548,076 | 545,985 | 563,040 | 556,382 | 559,363 |
| Reference price 2 | 3.400 | 4.570 | 5.010 | 8.980 | 6.370 | 6.130 |
| Announcement Date | 3/29/19 | 3/27/20 | 4/28/21 | 4/19/22 | 4/6/23 | 3/27/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 1,195 | 1,312 | 1,417 | 1,605 | 1,961 | 2,070 |
| EBITDA 1 | 113.7 | 145.8 | 117.3 | 163.9 | 39.37 | 126.8 |
| EBIT 1 | 62.83 | 106.7 | 76.23 | 120.3 | -7.866 | 75.94 |
| Operating Margin | 5.26% | 8.14% | 5.38% | 7.5% | -0.4% | 3.67% |
| Earnings before Tax (EBT) 1 | -115.3 | 51.23 | 29.24 | 7.45 | -82.85 | 42.96 |
| Net income 1 | -115.3 | 45.71 | 29.24 | 5.995 | -72.14 | 43.56 |
| Net margin | -9.65% | 3.48% | 2.06% | 0.37% | -3.68% | 2.1% |
| EPS 2 | -0.2009 | 0.0822 | 0.0535 | 0.0107 | -0.1283 | 0.0774 |
| Free Cash Flow 1 | -13.99 | -98.32 | -35.35 | 124.2 | 361.3 | -99.01 |
| FCF margin | -1.17% | -7.49% | -2.49% | 7.74% | 18.43% | -4.78% |
| FCF Conversion (EBITDA) | - | - | - | 75.77% | 917.55% | - |
| FCF Conversion (Net income) | - | - | - | 2,071.8% | - | - |
| Dividend per Share | - | - | 0.0160 | 0.0100 | - | - |
| Announcement Date | 3/29/19 | 3/27/20 | 4/28/21 | 4/19/22 | 4/6/23 | 3/27/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 408 | 562 | 630 | 559 | 280 | 430 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 3.586 x | 3.851 x | 5.366 x | 3.407 x | 7.101 x | 3.391 x |
| Free Cash Flow 1 | -14 | -98.3 | -35.3 | 124 | 361 | -99 |
| ROE (net income / shareholders' equity) | -7.96% | 3.33% | 1.87% | 0.41% | -4.46% | 2.77% |
| ROA (Net income/ Total Assets) | 1.39% | 2.39% | 1.51% | 2.1% | -0.13% | 1.32% |
| Assets 1 | -8,286 | 1,910 | 1,940 | 286 | 54,200 | 3,296 |
| Book Value Per Share 2 | 2.420 | 2.400 | 2.660 | 2.950 | 2.770 | 2.820 |
| Cash Flow per Share 2 | 1.170 | 0.7300 | 0.8900 | 0.6800 | 0.5500 | 0.3500 |
| Capex 1 | 66.4 | 108 | 72.7 | 39.1 | 66.6 | 43.1 |
| Capex / Sales | 5.56% | 8.21% | 5.13% | 2.44% | 3.4% | 2.08% |
| Announcement Date | 3/29/19 | 3/27/20 | 4/28/21 | 4/19/22 | 4/6/23 | 3/27/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -14.85% | 405M | |
| +33.43% | 700B | |
| +27.39% | 569B | |
| -5.12% | 358B | |
| +19.59% | 330B | |
| +4.89% | 287B | |
| +16.09% | 236B | |
| +6.54% | 202B | |
| -8.92% | 197B | |
| +4.26% | 161B |
- Stock Market
- Equities
- 600222 Stock
- Financials Henan Taloph Pharmaceutical Stock Co.,Ltd